Rosebud Biosciences
Growing micro-organs to find new drugs
What they do
Drug development is slow and inefficient because existing disease models often fail to match patient-specific genetics, limiting target discovery and predicting drug response—especially for rare and pediatric diseases.
The company grows patient-mutation-matched, fetal-like organoids to screen therapeutics and discover new drug targets for drug development and rare-disease drug discovery.
Pharmaceutical and therapeutics companies (and internal drug discovery teams) that need better preclinical models for screening and target discovery.
Founders
Kitch is CEO and co-founder of Rosebud Biosciences. He is a Physician-Scientist (MD, PhD) with 16 years’ experience merging human induced pluripotent stem cells with genomic and molecular technologies. A Stanford-trained molecular pathologist, Kitch was an attending physician at Stanford for 6 years before cofounding Rosebud.
Evan is co-founder and CTO of Rosebud Biosciences. Evan is a Scientist-Engineer (PhD) with 10 years’ experience in advanced microscopy, machine learning, and data engineering. At UC Berkeley he studied the neural coding of perception and was part of a team that built the first bidirectional brain machine interface with proven single cell resolution. Before joining Rosebud he contracted for startups as a data and ML engineer.
Company timeline
- Founded2020
- YC batchWinter 2022
- StatusActive
- Team size3 people
- LocationSan Francisco, CA, USA; San Carlos, CA, USA
Similar startups
